Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 5/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 4/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380004 | 0.83 | F10 (0.47) | — | |
| SCHEMBL5371113 | 0.83 | F10 (0.47) | — | |
| SCHEMBL5380643 | 0.81 | F10 (0.34) | HDAC8HDAC6 | |
| SCHEMBL5371161 | 0.81 | F10 (0.34) | HDAC8HDAC6 | |
| SCHEMBL5958870 | 0.77 | HDAC8 (0.37) | HDAC8HDAC6HTT | |
| SCHEMBL2698184 | 0.77 | HDAC8 (0.46) | HDAC8HDAC6HTT | |
| SCHEMBL5936077 | 0.75 | FPR2 (0.44) | HDAC8HDAC6CCNA2CDK2CCNA1 | |
| SCHEMBL5380049 | 0.75 | F10 (0.39) | — | |
| SCHEMBL8299294 | 0.75 | LIPE (0.38) | LIPECCNA2CDK2CCNA1 | |
| SCHEMBL5386312 | 0.74 | F10 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |